COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Randomized Phase II/III trial of adjuvant radiation therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in pathologic high-risk Squamous Cell Cancer of the head and neck

Protocol No
RTOG-1216
Principal Investigator
Christopher Schultz
Phase
II/III
Summary
First part of the study The purpose of the this part of this study is to find out what effects, good and/or bad, one of the following treatments has on you and your cancer. In this part of the study, you will receive one of the following treatments: 1. Standard treatment: radiation therapy and cisplatin 2. Experimental treatment: radiation therapy and docetaxel 3. Experimental treatment: radiation therapy, docetaxel, and cetuximab Second part of the study This part of the study will proceed only if certain results are achieved in the first part of the study. The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better. In this part of the study, you will get either the standard treatment or the experimental treatment.
Description
The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category